ScholarIQanswers from OpenAlex & ORCID
Sherko Kümmel
ResearcherPublications, citations & collaboration network
Sherko Kümmel is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Sherko Kümmel have?
ScholarIQindexed works
Sherko Kümmel has 515 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Sherko Kümmel have?
ScholarIQcitation count
Sherko Kümmel has 21,794 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Sherko Kümmel?
ScholarIQh-index
Sherko Kümmel has an h-index of 59 in OpenAlex.
What is the i10-index of Sherko Kümmel?
ScholarIQi10-index
Sherko Kümmel has an i10-index of 178 in OpenAlex.
What is the OpenAlex record for Sherko Kümmel?
ScholarIQopenalex
The OpenAlex for Sherko Kümmel is on the source record.
What are the most-cited papers on Sherko Kümmel?
ScholarIQmost cited works
Pembrolizumab for Early Triple-Negative Breast Cancer
Peter Schmid, Javier Cortés, Lajos Pusztai, Heather L. McArthur, Sherko Kümmel, Jonas Bergh, Carsten Denkert, Yeon Hee Park, Rina Hui, Nadia Harbeck, Masato Takahashi, Theodoros Foukakis, Peter A. Fasching, Fátima Cardoso, Michael Untch, Liyi Jia, Vassiliki Karantza, Jing Zhao, Gursel Aktan, Rebecca Dent, Joyce O’Shaughnessy
Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy
Carsten Denkert, Gϋnter von Minckwitz, Silvia Darb‐Esfahani, Bianca Lederer, Barbara Ingold Heppner, Karsten E. Weber, Jan Budczies, Jens Huober, Frederick Klauschen, Jenny Furlanetto, Wolfgang Schmitt, Jens‐Uwe Blohmer, Thomas Karn, Berit M. Pfitzner, Sherko Kümmel, Knut Engels, Andreas Schneeweiß, Arndt Hartmann, Aurelia Noske, Peter A. Fasching, Christian Jackisch, Marion van Mackelenbergh, Hans‐Peter Sinn, Christian Schem, Claus Hanusch, Michael Untch, Sibylle Loibl
Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial
Gϋnter von Minckwitz, Andreas Schneeweiß, Sibylle Loibl, Christoph Salat, Carsten Denkert, Mahdi Rezai, Jens‐Uwe Blohmer, Christian Jackisch, Stefan Paepke, Bernd Gerber, Dirk M. Zahm, Sherko Kümmel, Holger Eidtmann, Peter Klare, Jens Huober, Serban Dan Costa, Hans Tesch, Claus Hanusch, J. Hilfrich, F Khandan, Peter A. Fasching, Bruno V. Sinn, Knut Engels, Keyur Mehta, Valentina Nekljudova, Michael Untch
Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2–Positive and Triple-Negative Primary Breast Cancers
Carsten Denkert, Gϋnter von Minckwitz, Jan C. Brase, Bruno V. Sinn, Stephan Gade, Ralf Kronenwett, Berit M. Pfitzner, Christoph Salat, Sherene Loi, Wolfgang Schmitt, Christian Schem, Karin Fisch, Silvia Darb‐Esfahani, Keyur Mehta, Christos Sotiriou, Stephan Wienert, Peter Klare, Fabrice André, Frederick Klauschen, Jens‐Uwe Blohmer, Kristin Krappmann, Marcus Schmidt, Hans Tesch, Sherko Kümmel, Hans‐Peter Sinn, Christian Jackisch, Manfred Dietel, Toralf Reimer, Michael Untch, Sibylle Loibl
A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study
S. Loibl, Michael Untch, Nicole Burchardi, Jens Huober, Bruno V. Sinn, Jens‐Uwe Blohmer, Eva‐Maria Grischke, Jenny Furlanetto, Hans Tesch, Claus Hanusch, Knut Engels, Mahdi Rezai, Christian Jackisch, Wolfgang Schmitt, Gϋnter von Minckwitz, Jörg Thomalla, Sherko Kümmel, Beate Rautenberg, Peter A. Fasching, Karsten E. Weber, Kerstin Rhiem, Carsten Denkert, Andreas Schneeweiß